Artia Global Partners LP
CIK 1937964 · View on SEC EDGAR ↗
- Portfolio value
- $541.9M
- Positions
- 48
- As of
- June 30, 2026
#3,587 of 9,443 by 13F value · top 38.0%
Portfolio value QoQ: +8.5% 13F does not disclose cash
- Top 10 holdings weight
- 64.55%
- Top 25 holdings weight
- 88.35%
- Positions above 1%
- 23
- Effective number of positions
- 17.5
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 15.28% Est. buys $140,996,646 · sells $79,556,713
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 41.4% still held
- New positions
- 8
- Increased
- 11
- Decreased
- 3
- Closed
- 9
Put-notional exposure: 2.9% puts 13F reports option positions at underlying notional value — may include hedges, not necessarily bearish bets
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +26.3% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 93.3% · Options excluded: 10.1%
Sector breakdown
Healthcare
96.2%
Other/Unmapped
3.8%
Full portfolio 48 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| ABVX Abivax SA - American Depositary Shares | $68,821,727 | 12.70% | 516,447 | $1,928,549 | Down ×1 | ||
| INSM Insmed Incorporated - Common Stock | $62,804,724 | 11.59% | 589,052 | $-40,002,262 | Down ×4 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $41,232,390 | 7.61% | 2,210,852 | $17,210,118 | Up ×1 | ||
| BTSG BrightSpring Health Services, Inc. - Common Stock | $36,077,548 | 6.66% | 517,315 | $33,785,130 | Up ×2 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $34,719,839 | 6.41% | 185,390 | $22,564,561 | Up ×2 | ||
| ARGX argenx SE - American Depositary Shares | $27,590,952 | 5.09% | 29,739 | $5,874,047 | |||
| ALKS Alkermes plc - Ordinary Shares | $23,523,469 | 4.34% | 448,964 | Up ×1 | |||
| TVTX Travere Therapeutics, Inc. - Common Stock | $19,260,465 | 3.55% | 339,033 | $17,159,968 | Up ×1 | ||
| AZN AstraZeneca PLC - American Depositary Shares | $18,654,057 | 3.44% | 98,376 | $-155,998 | Up ×1 | ||
| NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares | $17,078,391 | 3.15% | 503,936 | $947,400 | |||
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $15,888,265 | 2.93% | 162,990 | $2,210,144 | |||
| XBI XBI | $15,825,000 | 2.92% | 100,000 | Put option | |||
| DGX Quest Diagnostics Incorporated Common Stock | $13,802,608 | 2.55% | 65,122 | $5,803,292 | Up ×1 | ||
| IONS Ionis Pharmaceuticals, Inc. - Common Stock | $11,447,573 | 2.11% | 144,376 | $606,379 | |||
| EYPT EyePoint, Inc. - Common Stock | $10,969,501 | 2.02% | 767,098 | $1,081,608 | |||
| ALMS Alumis Inc. - Common Stock | $7,838,284 | 1.45% | 278,546 | $677,521 | Down ×1 | ||
| VKTX Viking Therapeutics, Inc. - Common Stock | $7,050,316 | 1.30% | 180,731 | $1,169,329 | |||
| CELC Celcuity Inc. - Common Stock | $6,205,640 | 1.15% | 59,316 | $4,427,795 | Up ×2 | ||
| CYTK Cytokinetics, Incorporated - Common Stock | $6,022,933 | 1.11% | 70,700 | $4,948,600 | Up ×1 | ||
| MRK Merck & Company, Inc. Common Stock (new) | $6,000,950 | 1.11% | 46,700 | $383,407 | |||
| RAPP Rapport Therapeutics, Inc. - Common Stock | $5,771,628 | 1.07% | 138,508 | $1,437,713 | |||
| JNJ Johnson & Johnson Common Stock | $5,739,722 | 1.06% | 22,600 | $215,378 | |||
| GH Guardant Health, Inc. - Common Stock | $5,716,143 | 1.05% | 38,100 | Up ×1 | |||
| ABSI Absci Corporation - Common Stock | $5,382,906 | 0.99% | 464,444 | Up ×1 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $5,295,675 | 0.98% | 96,285 | $562,304 | |||
| SION Sionna Therapeutics, Inc. - Common Stock | $5,267,407 | 0.97% | 119,741 | $466,990 | |||
| Unknown issuer (CUSIP: K08588103) | $4,731,613 | 0.87% | 17,740 | Up ×1 | |||
| ROIV Roivant Sciences Ltd. - Common Shares | $4,593,622 | 0.85% | 129,800 | $998,162 | |||
| PALI Palisade Bio, Inc. - Common Stock | $4,164,047 | 0.77% | 1,992,367 | $677,405 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $4,014,244 | 0.74% | 98,800 | $1,950,994 | Up ×1 | ||
| BIIB Biogen Inc. - Common Stock | $3,983,498 | 0.74% | 18,437 | $603,443 | |||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $3,923,400 | 0.72% | 65,000 | $143,650 | |||
| BLTE Belite Bio, Inc - American Depositary Shares | $3,847,931 | 0.71% | 24,989 | $-136,315 | |||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $3,717,844 | 0.69% | 137,800 | $-15,158 | |||
| PROK ProKidney Corp. - Class A Ordinary Shares | $3,686,156 | 0.68% | 1,806,939 | $451,735 | |||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $3,659,075 | 0.68% | 72,100 | $2,839,795 | Up ×1 | ||
| ORKA Oruka Therapeutics, Inc. - Common Stock | $3,178,678 | 0.59% | 33,400 | ||||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $2,813,334 | 0.52% | 22,951 | $396,407 | Up ×1 | ||
| UTHR United Therapeutics Corporation - Common Stock | $2,709,150 | 0.50% | 5,000 | $-255,750 | |||
| DRUG Bright Minds Biosciences Inc. - common stock | $2,696,171 | 0.50% | 38,407 | $-106,388 | |||
| KNSA Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares | $1,867,340 | 0.34% | 29,200 | $461,360 | |||
| CMPX Compass Therapeutics, Inc. - Common Stock | $839,208 | 0.15% | 383,200 | Up ×1 | |||
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $836,975 | 0.15% | 2,500 | $31,500 | |||
| KOD Kodiak Sciences Inc - Common Stock | $663,060 | 0.12% | 17,019 | $14,296 | |||
| TENX Tenax Therapeutics, Inc. - Common Stock | $612,264 | 0.11% | 42,080 | $-60,595 | |||
| NUVL Nuvalent, Inc. - Class A Common Stock | $605,150 | 0.11% | 4,900 | $103,145 | |||
| PEPG PepGen Inc. - Common Stock | $369,583 | 0.07% | 205,324 | $6,160 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $355,120 | 0.07% | 4,000 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| INSM | Trimmed | -40K | -$40.0M |
| RVMD | Bought more | +60K | +$22.6M |
| TRVI | Bought more | +197K | +$17.2M |
| ARGX | Price move only | +0 | +$5.9M |
| DGX | Bought more | +24K | +$5.8M |
| CELC | Bought more | +44K | +$4.4M |
| ELVN | Bought more | +51K | +$2.8M |
| DNTH | Price move only | +0 | +$2.2M |
| EWTX | Bought more | +33K | +$2.0M |
| ABVX | Trimmed | -84K | +$1.9M |
3 positions hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| VRNA | Dec. 31, 2025 | 379,004 | $40,443,517 | No longer tracked |
| NVO | March 31, 2025 | 450,000 | $38,709,000 | -32.7% |
| LLY | June 30, 2026 | 38,220 | $35,153,609 | 4.2% |
| UGL | March 31, 2026 | 542,119 | $30,098,447 | No longer tracked |
| ITCI | June 30, 2025 | 219,719 | $28,985,330 | No longer tracked |
| MRUS | Dec. 31, 2025 | 296,750 | $27,939,013 | No longer tracked |
| QURE | March 31, 2026 | 1,023,539 | $24,493,288 | 202.3% |
| VRTX | Dec. 31, 2025 | 55,100 | $21,579,364 | 20.6% |
| BSX | Dec. 31, 2025 | 183,200 | $17,885,816 | -48.2% |
| CDTX | March 31, 2026 | 70,824 | $15,644,313 | No longer tracked |
| ACLX | June 30, 2025 | 229,085 | $15,027,976 | No longer tracked |
| PCVX | March 31, 2025 | 162,255 | $13,282,194 | 65.0% |
| MRNA | June 30, 2026 | 200,000 | $10,160,000 | 104.3% |
| XBI | March 31, 2025 | 100,000 | $9,006,000 | No longer tracked |
| XBI | Sept. 30, 2025 | 100,000 | $8,293,000 | No longer tracked |
| ALNY | March 31, 2026 | 17,400 | $6,919,110 | -30.6% |
| RARE | Dec. 31, 2025 | 214,502 | $6,452,220 | 13.6% |
| NUVL | June 30, 2025 | 90,745 | $6,435,635 | No longer tracked |
| VTYX | March 31, 2026 | 695,982 | $6,284,717 | No longer tracked |
| PVLA | March 31, 2026 | 59,200 | $6,196,464 | 16.2% |
| REGN | Dec. 31, 2025 | 10,671 | $5,999,983 | 8.5% |
| TERN | June 30, 2026 | 104,800 | $5,525,056 | No longer tracked |
| RNA | March 31, 2026 | 60,100 | $4,335,013 | -1.8% |
| ASND | June 30, 2026 | 17,740 | $4,057,670 | -3.3% |
| NKTR | Dec. 31, 2025 | 57,999 | $3,300,143 | 77.7% |
| CNTA | Dec. 31, 2025 | 133,291 | $3,232,307 | No longer tracked |
| ABBV | June 30, 2026 | 14,500 | $3,153,605 | 4.8% |
| SWTX | Sept. 30, 2025 | 63,930 | $3,004,071 | No longer tracked |
| OCUL | March 31, 2026 | 226,261 | $2,746,809 | 33.1% |
| RYTM | June 30, 2025 | 50,000 | $2,648,500 | 73.7% |
| CRNX | March 31, 2025 | 45,765 | $2,339,964 | 152.7% |
| ELVN | March 31, 2025 | 102,900 | $2,315,250 | 201.6% |
| SLNO | June 30, 2026 | 68,490 | $2,293,045 | No longer tracked |
| VRDN | June 30, 2025 | 160,000 | $2,156,800 | 76.1% |
| TGTX | Dec. 31, 2025 | 54,515 | $1,969,354 | 85.1% |
| UPB | March 31, 2026 | 68,653 | $1,863,929 | -22.7% |
| ISRG | June 30, 2025 | 3,500 | $1,733,445 | -31.2% |
| NBIX | June 30, 2025 | 14,700 | $1,625,820 | 22.6% |
| IREN | Dec. 31, 2025 | 33,200 | $1,558,076 | 19.6% |
| BBIO | June 30, 2026 | 20,400 | $1,514,904 | 11.0% |
| NAMS | March 31, 2025 | 54,285 | $1,395,124 | 36.8% |
| EWTX | March 31, 2025 | 50,000 | $1,335,000 | 99.5% |
| BHVN | Dec. 31, 2025 | 80,000 | $1,200,800 | 26.3% |
| CRL | March 31, 2025 | 6,305 | $1,163,903 | 92.8% |
| TARS | March 31, 2025 | 20,811 | $1,152,305 | 40.7% |
| MREO | Dec. 31, 2025 | 475,361 | $979,244 | -29.0% |
| ANNX | March 31, 2025 | 172,226 | $883,519 | 169.4% |
| SRPT | Dec. 31, 2025 | 44,900 | $865,223 | -9.1% |
| TECX | March 31, 2025 | 16,650 | $768,731 | 113.0% |
| ATYR | Dec. 31, 2025 | 972,276 | $701,400 | -33.6% |
| MRNA | Dec. 31, 2025 | 23,800 | $614,754 | 385.3% |
| ANRO | March 31, 2026 | 29,192 | $519,618 | 54.2% |
| CNTA | June 30, 2025 | 35,226 | $506,550 | No longer tracked |
| KALV | Dec. 31, 2025 | 41,555 | $506,140 | No longer tracked |
| APGE | June 30, 2026 | 5,886 | $495,425 | 1.6% |
| JANX | Sept. 30, 2025 | 20,000 | $462,000 | -28.1% |
| AVTX | June 30, 2026 | 28,970 | $432,522 | 8.2% |
| ALEC | Dec. 31, 2025 | 71,029 | $210,246 | 45.8% |
| ORKA | June 30, 2025 | 7,380 | $75,719 | 854.0% |
| LYRA | March 31, 2026 | 8,756 | $26,968 | No longer tracked |